骨桥蛋白在肝细胞癌诊治中的作用

吴寒; 李镇利; 邢昊; 王明达; 吴孟超; 杨田

doi:10.3969/j.issn.1001-5256.2018.09.036

骨桥蛋白在肝细胞癌诊治中的作用

DOI: 10.3969/j.issn.1001-5256.2018.09.036

海军军医大学附属东方肝胆医院肝胆外科

基金项目:

国家自然科学基金(81472284,81172020,81372262)；上海市慈善慢跑课题(20130007)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2141
- HTML全文浏览量: 28
- PDF下载量: 383
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-27
- 出版日期: 2018-09-20

Research advances in the structure and function of osteopontin and its effect in diagnosis and treatment of hepatocellular carcinoma

Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University

Research funding:

摘要

摘要: 骨桥蛋白(OPN)是一种分布广泛的分泌蛋白,主要参与整合素介导的细胞信号转导,在HCC的发生发展和转移过程中发挥重要作用。OPN在生物矿化和固有免疫中发挥重要作用,通过与整合素相互作用参与肿瘤生长和血管生成,通过多重信号转导诱导肝癌复发和转移。OPN与其他肿瘤标志物的联合检测评估,有利于提高早期HCC诊断敏感性。OPN抑制剂可能成为HCC治疗的新靶点,并有利于提高化疗药物的敏感性。总结了近年针对OPN的研究,对其生物学功能及其在HCC进展和诊疗中的作用进行介绍。
- 癌,肝细胞 /
- 骨桥蛋白质 /
- 综述
Abstract: Osteopontin (OPN) is a widely distributed secretory protein and is involved in integrin-mediated cell signal transduction. It also plays an important role in the development, progression, and metastasis of hepatocellular carcinoma (HCC) . OPN plays a pivotal role in biomineralization and innate immunity, participates in tumor growth and angiogenesis by interacting with integrin, and induces the recurrence and metastasis of HCC via multiple signal transduction. Combined measurement of OPN and other tumor biomarkers can improve the sensitivity of early diagnosis of HCC. OPN inhibitors may serve as a new target for the treatment of HCC and can improve the sensitivity of chemotherapeutic drugs. This article summarizes the recent studies on OPN and introduces the biological function of OPN and its role in the progression and diagnosis and treatment of HCC.
- carcinoma, hepatocellular /
- osteopontin /
- review

HTML全文

参考文献(54)

[1]NUEZ-GARCIA M, GOMEZ-SANTOS B, BUQUX, et al.Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver[J].J Lipid Res, 2017, 58 (9) :1903-1915.

[2]HAO C, CUI Y, OWEN S, et al.Human osteopontin:Potential clinical applications in cancer (Review) [J].Int J Mol Med, 2017, 39 (6) :1327-1337.

[3]HOAC B, NELEA V, JIANG W, et al.Mineralization-inhibiting effects of transglutaminase-crosslinked polymeric osteopontin[J].Bone, 2017, 101:37-48.

[4]ANUNOBI CC, KOLI K, SAXENA G, et al.Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms[J].Oncotarget, 2016, 7 (30) :48038-48049.

[5]FISHER LW, TORCHIA DA, FOHR B, et al.Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin[J].Biochem Biophys Res Commun, 2001, 280 (2) :460-465.

[6]FISHER LW, JAIN A, TAYBACK M, et al.Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers[J].Clin Cancer Res, 2004, 10 (24) :8501-8511.

[7]EL-TANANI MK.Role of osteopontin in cellular signaling and metastatic phenotype[J].Front Biosci, 2008, 13:4276-4284.

[8]DENHARDT DT, GUO X.Osteopontin:A protein with diverse functions[J].FASEB J, 1993, 7 (15) :1475-1482.

[9]CAO DX, LI ZJ, JIANG XO, et al.Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers[J].World J Gastroenterol, 2012, 18 (30) :3923-3930.

[10]WANG G, CHEN S, ZHAO C, et al.Comparative analysis of gene expression profiles of OPN signaling pathway in four kinds of liver diseases[J].J Genet, 2016, 95 (3) :741-750.

[11]KLNING E, CHRISTENSEN B, BAJIC G, et al.Multiple low-affinity interactions support binding of human osteopontin to integrinαXβ2[J].Biochim Biophys Acta, 2015, 1854 (8) :930-938.

[12]CHEN Q, SHOU P, ZHANG L, et al.An osteopontin-integrin interaction plays a critical role in directing adipogenesis and osteogenesis by mesenchymal stem cells[J].Stem Cells, 2014, 32 (2) :327-337.

[13]JIN Y, CHEN JN, FENG ZY, et al.OPN andαvβ3 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma[J].PLo S One, 2014, 9 (2) :e87930.

[14]ZHANG H, GUO M, CHEN JH, et al.Osteopontin knockdown inhibitsαv, β3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/m TOR pathway[J].Cell Physiol Biochem, 2014, 33 (4) :991-1002.

[15]KALE S, RAJA R, THORAT D, et al.Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth viaα9β1 integrin[J].Oncogene, 2014, 33 (18) :2295-2306.

[16]GERICKE A, QIN C, SPEVAK L, et al.Importance of phosphorylation for osteopontin regulation of biomineralization[J].Calcif Tissue Int, 2005, 77 (1) :45-54.

[17]WANG KX, DENHARDT DT.Osteopontin:Role in immune regulation and stress responses[J].Cytokine Growth Factor Rev, 2008, 19 (5-6) :333-345.

[18]MIYAZAKI K, OKADA Y, YAMANAKA O, et al.Corneal wound healing in an osteopontin-deficient mouse[J].Invest Ophthalmol Vis Sci, 2008, 49 (4) :1367-1375.

[19]SUBRAMAN V, THIYAGARAJAN M, MALATHI N, et al.OPN-revisited[J].J Clin Diagn Res, 2015, 9 (6) :ZE10-13.

[20]WEI R, JPC W, KWOK HF.Osteopontin-a promising biomarker for cancer therapy[J].J Cancer, 2017, 8 (12) :2173-2183.

[21]TILLI TM, FRANCO VF, ROBBS BK, et al.Osteopontin-c splicing isoform contributes to ovarian cancer progression[J].Mol Cancer Res, 2011, 9 (3) :280-293.

[22]NG L, WAN TM, LAM CS, et al.Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer[J].PLo S One, 2015, 10 (5) :e0126219.

[23]STEINMAN L.A molecular trio in relapse and remission in multiple sclerosis[J].Nat Rev Immunol, 2009, 9 (6) :440-447.

[24]LI J, CHEN X, DAI M, et al.Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma:A metaanalysis[J].Clin Res Hepatol Gastroenterol, 2017, 41 (5) :543-553.

[25]JANG ES, JEONG SH, KIM JW, et al.Diagnostic performance of Alpha-fetoprotein, protein induced by vitamin K absence, Osteopontin, Dickkopf-1 and its combinations for hepatocellular carcinoma[J].PLo S One, 2016, 11 (3) :e0151069.

[26]CABIATI M, GAGGINI M, CESARE MM, et al.Osteopontin in hepatocellular carcinoma:A possible biomarker for diagnosis and follow-up[J].Cytokine, 2017, 99:59-65.

[27]ABU EMMA, ABDEL-ALEEM A, ALI A, et al.Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma[J].Ann Hepatol, 2011, 10 (3) :296-305.

[28]SIMO A, MADALENO J, SILVA N, et al.Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening[J].BMC Gastroenterol, 2015, 15:73.

[29]ZHOU C, ZHOU HJ, ZHANG XF, et al.Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma[J].Ann Surg Oncol, 2013, 20 (3) :929-937.

[30]ZHAO J, DONG L, LU B, et al.Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis[J].Gastroenterology, 2008, 135 (3) :956-968.

[31]FAN X, HE C, JING W, et al.Intracellular osteopontin inhibits toll-like receptor signaling and impedes liver carcinogenesis[J].Cancer Res, 2015, 75 (1) :86-97.

[32]YE QH, QIN LX, FORGUES M, et al.Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning[J].Nat Med, 2003, 9 (4) :416-23.

[33]LIU XS.Experimental study of effect on biological behavior of hepatic cells by osteopontin and anti-sense osteopontin[D].Suzhou:Suzhou Univ, 2004. (in Chinese) 刘希胜.骨桥蛋白及其反义基因对肝癌细胞浸润的生物学行为实验研究[D].苏州:苏州大学, 2004.

[34]LIKUI W, HONG W, SHUWEN Z, et al.The potential of osteopontin as a therapeutic target for human colorectal cancer[J].JGastrointest Surg, 2011, 15 (4) :652-659.

[35]TRIERWEILER C, HOCKENJOS B, ZATLOUKAL K, et al.The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice[J].Cell Death Differ, 2016, 23 (4) :576-582.

[36]SUN BS, DONG QZ, YE QH, et al.Lentiviral-mediated miRNAagainst osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma[J].Hepatology, 2008, 48 (6) :1834-1842.

[37]SILVA I, RAUSCH V, SEITZ HK, et al.Does hypoxia cause carcinogenic iron accumulation in alcoholic liver disease (ALD) ?[J].Cancers (Basel) , 2017, 9 (11) :145.

[38]WANG C, HAN C, ZHANG Y, et al.LncRNA PVT1 regulate expression of HIF1αvia functioning as ceRNA for miR-199a-5p in non-small cell lung cancer under hypoxia[J].Mol Med Rep, 2017, 17 (1) :1105-1110.

[39]WANG CQ, SUN HT, GAO XM, et al.Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression[J].Am J Cancer Res, 2016, 6 (9) :1873-1889.

[40]HOLLENBACH M.The role of glyoxalase-I (Glo-I) , advanced glycation endproducts (AGEs) , and their receptor (RAGE) in chronic liver disease and hepatocellular carcinoma (HCC) [J].Int J Mol Sci, 2017, 18 (11) :2466.

[41]AWAN FM, NAZ A, OBAID A, et al.Identification of circulating biomarker candidates for hepatocellular carcinoma (HCC) :An integrated prioritization approach[J].PLo S One, 2015, 10 (9) :e0138913.

[42]ZHU W, GUO L, ZHANG B, et al.Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection[J].Ann Surg Oncol, 2014, 21 (4) :1304-1313.

[43]WAIDELY E, AL-YUOBI AR, BASHAMMAKH AS, et al.Serum protein biomarkers relevant to hepatocellular carcinoma and their detection[J].Analyst, 2016, 141 (1) :36-44.

[44]WITJES CD, van AALTEN SM, STEYERBERG EW, et al.Recently introduced biomarkers for screening of hepatocellular carcinoma:A systematic review and meta-analysis[J].Hepatol Int, 2013, 7 (1) :59-64.

[45]MARRERO JA, FENG Z, WANG Y, et al.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma[J].Gastroenterology, 2009, 137 (1) :110-118.

[46]XU Z, LIU L, PAN X, et al.Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease[J].Medicine (Baltimore) , 2015, 94 (12) :e659.

[47]ZHANG J, ZHAO Y, YANG Q.Sensitivity and specificity of Dickkopf-1 protein in serum for diagnosing hepatocellular carcinoma:Ameta-analysis[J].Int J Biol Markers, 2014, 29 (4) :e403-e410.

[48]MOHAMMADI S, GHAFFARI SH, SHAIEGAN M, et al.Curcumin veto the effects of Osteopontin (OPN) specific inhibitor on leukemic stem cell colony forming potential via promotion of OPN overexpression[J].Int J Hematol Oncol Stem Cell Res, 2016, 10 (3) :120-129.

[49]WU XL, LIN KJ, BAI AP, et al.Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells[J].World JGastroenterol, 2014, 20 (30) :10440-10448.

[50]GRBCˇIC'P, TOMLJANOVIC'I, KLOBUCˇAR M, et al.Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling[J].Biochem Biophys Res Commun, 2017, 487 (4) :782-788.

[51]PETROCCA F, LIEBERMAN J.Micromanipulating cancer:microRNA-based therapeutics?[J].RNA Biol, 2009, 6 (3) :335-340.

[52]QIN S, ZHANG Z, LI J, et al.FRZB knockdown upregulatesβ-catenin activity and enhances cell aggressiveness in gastric cancer[J].Oncol Rep, 2014, 31 (5) :2351-2357.

[53]LIN F, HUANG CM, CAO J, et al.Segment-specific targeting via RNA interference mediates down-regulation of OPN expression in hepatocellular carcinoma cells[J].Genet Mol Res, 2015, 14 (4) :14440-14447.

[54]LIU G, FAN X, TANG M, et al.Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells[J].Cancer Lett, 2016, 383 (2) :171-182.

施引文献

资源附件(0)

访问统计